This trial is evaluating whether Treatment will improve 1 primary outcome and 8 secondary outcomes in patients with Hot Flashes. Measurement will happen over the course of Up to 12 weeks following intervention.
This trial requires 160 total participants across 2 different treatment groups
This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.
Hot flashes cannot be cured. Instead, medical specialists prescribe medications that reduce the frequency and severity of the common symptoms associated with hot flashes. Since most women who have symptoms of menopausal hot flashes do not have vasomotor symptoms for longer than 6 months, they are advised to initiate the most effective medications at the start of the menopausal transition (after breast cessation to prevent breast cancer) and continue taking those medications until symptomatic control is achieved.
Hot flashes are common symptoms that can affect an elderly woman's quality of life. Physicians should ask patients about the signs and symptoms of hot flashes and discuss ways to manage them.
Between 2.3 and 3.0 million women annually in the USA report moderate to severe hot flashes requiring either medical treatment or a change in sexual activity.\n
Treatments for hot flashes vary by type. In almost every case, a hormone (e.g., oestrogen) is typically ineffective and can cause serious health side effects. Although not all women experience hot flashes, many treatments can have a high rate of success in treating the condition.
Hot flashes are common events in menopause and women with prostate cancer. They are associated with a variety of physical and emotional symptoms. There is a need to create a more holistic approach to addressing problems associated with hot flashes in menopause.
hot flashes occur after any condition that question: What causes hot flashes? answer: Symptoms like excessive sweating or flushing may suggest hot flashes. Hot flashes are usually of the low-grade type and may occur after other conditions,
Treatment with GnRH agonists and androscoginol has been described as being associated with nausea, vomiting, pain, breast tenderness, hot flashes, fatigue, hypoglycaemia, decreased libido, galactorrhoea, vaginal bleeding, amenorrhea, vaginal stenosis, increased urinary frequency, urinary incontinence, arthralgia and/or arthralgias, headache, loss of vision, eye pain, blurred vision, and in a few instances visual disturbances. The side effects experienced by patients have ranged widely in number and character from mild to severe.
The findings of this analysis strengthen the likelihood of familial heterogeneity for hot flashes, and may have an implication for genetic studies in this area.
Although most women with hot flashes felt that they needed clinical trials to relieve hot flashes and all felt that the information they obtained from a clinical trial would help them, many were unable to use clinical trial data to make an informed decision about the best short term treatment. Hot flashes were perceived as a personal problem rather than a medical issue and many women were unconcerned with any information about the risk and benefits of placebo. This suggests that clinical trials on hot flashes should be used not only to assess safety and evaluate medication efficacy, but also to improve women's satisfaction with information on which to make good decisions about their health care.
Hot flashes normally happen at about 45 years old, but can happen at any age. While hot flashes can be disabling, they can happen with other menopausal symptoms as well. There is no “normal” average age of menopause.
Results from a recent clinical trial suggest that improvements in HRQL scores may improve sleep disturbances and QOL in patients with breast cancer undergoing antiestrogen therapy despite improvement in hot flashes or the presence of low-grade febrile neutropenia.
There is no evidence that newer agents and technology are effective. Most symptomatic care is for management to decrease pain symptoms, improving the patient experience. These treatments should be reassessed in randomized studies of the appropriateness of the management of the symptoms of the patient for these agents and the technology.